Search results for "wt"

showing 10 items of 5424 documents

Vascular Endothelial Growth Factor, a Key Modulator of the Anti-Tumor Immune Response

2021

During tumor growth, angiogenesis is required to ensure oxygen and nutrient transport to the tumor. Vascular endothelial growth factor (VEGF) is the major inducer of angiogenesis and appears to be a key modulator of the anti-tumor immune response. Indeed, VEGF modulates innate and adaptive immune responses through direct interactions and indirectly by modulating protein expressions on endothelial cells or vascular permeability. The inhibition of the VEGF signaling pathway is clinically approved for the treatment of several cancers. Therapies targeting VEGF can modulate the tumor vasculature and the immune response. In this review, we discuss the roles of VEGF in the anti-tumor immune respon…

Vascular Endothelial Growth Factor AAngiogenesisAngiogenesis InhibitorsVascular permeabilityReviewAdaptive Immunityimmune responsechemistry.chemical_compoundangiogenesisNeoplasmsVEGF Signaling PathwayInducerBiology (General)SpectroscopyNeovascularization Pathologicvascular endothelial growth factorGeneral MedicineSorafenibComputer Science ApplicationsBevacizumabGene Expression Regulation NeoplasticVascular endothelial growth factorVascular endothelial growth factor AChemistrySignal TransductionQH301-705.5Recombinant Fusion ProteinsAntibodies Monoclonal HumanizedCatalysisCapillary PermeabilityInorganic ChemistryImmune systemmedicineHumansImmunologic FactorscancerPhysical and Theoretical ChemistryMolecular BiologyQD1-999Vascular Endothelial Growth Factor Receptor-1business.industryOrganic ChemistryEndothelial CellsCancermedicine.diseaseImmunity InnateReceptors Vascular Endothelial Growth FactorchemistryCancer researchbusinessInternational Journal of Molecular Sciences
researchProduct

Human Fetal Aorta Contains Vascular Progenitor Cells Capable of Inducing Vasculogenesis, Angiogenesis, and Myogenesis in Vitro and in a Murine Model …

2007

Vasculogenesis, the formation of blood vessels in embryonic or fetal tissue mediated by immature vascular cells (ie, angioblasts), is poorly understood. We report the identification of a population of vascular progenitor cells (hVPCs) in the human fetal aorta composed of undifferentiated mesenchymal cells that coexpress endothelial and myogenic markers. Under culture conditions that promoted cell differentiation, hVPCs gave rise to a mixed population of mature endothelial and mural cells when progenitor cells were stimulated with vascular endothelial growth factor-A or platelet-derived growth factor-betabeta. hVPCs grew as nonadherent cells and, when embedded in a three-dimensional collagen…

Vascular Endothelial Growth Factor AAngiogenesisBecaplerminNeovascularization PhysiologicAntigens CD34BiologyMuscle DevelopmentMural cellPathology and Forensic MedicineAngiopoietin-2MiceFetusVasculogenesisAntigens CDIschemiaAnimalsHumansCell LineageAC133 AntigenProgenitor cellAortaCells CulturedGlycoproteinsPlatelet-Derived Growth FactorStem CellsProto-Oncogene Proteins c-sisVascular Endothelial Growth Factor Receptor-2Cell biologyEndothelial stem cellVascular endothelial growth factor BVascular endothelial growth factor AVascular endothelial growth factor CImmunologyBlood VesselsPeptidesBiomarkersRegular ArticlesThe American Journal of Pathology
researchProduct

The hypoxia-inducible factor-responsive proteins semaphorin 4D and vascular endothelial growth factor promote tumor growth and angiogenesis in oral s…

2012

Growth and metastasis of solid tumors requires induction of angiogenesis to ensure the delivery of oxygen, nutrients and growth factors to rapidly dividing transformed cells. Through either mutations, hypoxia generated by cytoreductive therapies, or when a malignancy outgrows its blood supply, tumor cells undergo a change from an avascular to a neovascular phenotype, a transition mediated by the hypoxia-inducible factor (HIF) family of transcriptional regulators. Vascular endothelial growth factor (VEGF) is one example of a gene whose transcription is stimulated by HIF. VEGF plays a crucial role in promoting tumor growth and survival by stimulating new blood vessel growth in response to suc…

Vascular Endothelial Growth Factor AAngiogenesisSEMA4DSemaphorinsBiologyArticleVEGForal squamous cell carcinomasemaphorin 4Dhypoxia-inducible factorMicechemistry.chemical_compoundSemaphorinAntigens CDSettore BIO/10 - BiochimicaAnimalsHumansCells CulturedCell ProliferationNeovascularization PathologicNeoplasms ExperimentalCell BiologyOxygen tensionVascular endothelial growth factorVascular endothelial growth factor AHEK293 CellsHIF1AHypoxia-inducible factorschemistryImmunologyCarcinoma Squamous CellCancer researchMouth NeoplasmsExperimental Cell Research
researchProduct

Concomitant Use of Statins, Metformin, or Proton Pump Inhibitors in Patients with Advanced Renal Cell Carcinoma Treated with First-Line Combination T…

2022

Background Drug-drug interactions are a major concern in oncology and may potentially affect the outcome of patients with cancer. Objective In this study, we aimed to determine whether the concomitant use of statins, metformin, or proton pump inhibitors affects survival in patients with metastatic renal cell carcinoma treated with first-line combination therapies. Methods Medical records of patients with documented metastatic renal cell carcinoma between January 2016 and November 2021 were reviewed at 17 participating centers. This research was conducted in ten institutions, including both referral centers and local hospitals. Patients were assessed for overall survival, progression-free su…

Vascular Endothelial Growth Factor ACancer ResearchAngiogenesis InhibitorsProton Pump InhibitorsKidney NeoplasmsMetforminTreatment OutcomeOncologyHumansPharmacology (medical)Hydroxymethylglutaryl-CoA Reductase InhibitorsCarcinoma Renal CellProtein Kinase InhibitorsRetrospective StudiesTargeted oncology
researchProduct

Endothelin-1-Mediated Drug Resistance in EGFR-Mutant Non-Small Cell Lung Carcinoma.

2020

Abstract Progression on therapy in non-small cell lung carcinoma (NSCLC) is often evaluated radiographically, however, image-based evaluation of said therapies may not distinguish disease progression due to intrinsic tumor drug resistance or inefficient tumor penetration of the drugs. Here we report that the inhibition of mutated EGFR promotes the secretion of a potent vasoconstrictor, endothelin-1 (EDN1), which continues to increase as the cells become resistant with a mesenchymal phenotype. As EDN1 and its receptor (EDNR) is linked to cancer progression, EDNR-antagonists have been evaluated in several clinical trials with disappointing results. These trials were based on a hypothesis that…

Vascular Endothelial Growth Factor ACancer ResearchLung NeoplasmsAmbrisentanOncology and CarcinogenesisDrug ResistanceBiological AvailabilityAntineoplastic AgentsDrug resistanceCell LineMiceErlotinib HydrochlorideGefitinibIn vivomedicineAnimalsHumansOncology & CarcinogenesisNon-Small-Cell LungProtein Kinase InhibitorsLungCancerTumor microenvironmentTumorEndothelin-1business.industryCarcinomaLung CancerCancerEvaluation of treatments and therapeutic interventionsGefitinibmedicine.diseaseEndothelin 1Xenograft Model Antitumor AssaysErbB ReceptorsOncologyVasoconstriction5.1 Pharmaceuticals6.1 PharmaceuticalsCancer cellMutationCancer researchNeoplasmDevelopment of treatments and therapeutic interventionsbusinessmedicine.drug
researchProduct

VEGF-targeted therapy stably modulates the glycolytic phenotype of tumor cells

2014

Abstract Anti-VEGF therapy perturbs tumor metabolism, severely impairing oxygen, glucose, and ATP levels. In this study, we investigated the effects of anti-VEGF therapy in multiple experimental tumor models that differ in their glycolytic phenotypes to gain insights into optimal modulation of the metabolic features of this therapy. Prolonged treatments induced vascular regression and necrosis in tumor xenograft models, with highly glycolytic tumors becoming treatment resistant more rapidly than poorly glycolytic tumors. By PET imaging, prolonged treatments yielded an increase in both hypoxic and proliferative regions of tumors. A selection for highly glycolytic cells was noted and this met…

Vascular Endothelial Growth Factor ACancer ResearchPathologymedicine.medical_specialtyNecrosismedicine.medical_treatmentAngiogenesis InhibitorsMice SCIDBiologySCIDAntibodies Monoclonal HumanizedAntibodiesCell LineTargeted therapyMiceRandom AllocationCell Line TumorNeoplasmsMonoclonalAngiogenesis Inhibitors; Animals; Antibodies Monoclonal Humanized; Bevacizumab; Cell Line Tumor; Female; Glycolysis; Humans; MCF-7 Cells; Mice; Mice Inbred BALB C; Mice SCID; Molecular Targeted Therapy; Neoplasms; Phenotype; Random Allocation; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor AssaysmedicineAnimalsHumansGlycolysisMolecular Targeted Therapycancer-cellAnti-VEGF therapyHumanizedInbred BALB CMED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIAMice Inbred BALB CTumorpositron emission tomography antiangiogenesis glucose metabolism hypoxiaXenograft Model Antitumor AssaysPhenotypeBlockadeBevacizumabVascular endothelial growth factor APhenotypeOncologyCell cultureMonoclonalMCF-7 CellsCancer researchMED/06 - ONCOLOGIA MEDICAFemalemedicine.symptomGlycolysis
researchProduct

An Open-Label Phase II Study Evaluating the Safety and Efficacy of Ramucirumab Combined With mFOLFOX-6 as First-Line Therapy for Metastatic Colorecta…

2014

Abstract Author Summary Background. Vascular endothelial growth factor (VEGF) and VEGF receptor 2 (VEGFR-2) are believed to mediate angiogenesis in colorectal cancer (CRC). Ramucirumab (RAM; IMC-1121B) is a human IgG1 monoclonal antibody that inhibits VEGF ligand binding to VEGFR-2, inhibiting VEGFR-2 activation and signaling. Methods. Patients with metastatic CRC, Eastern Cooperative Oncology Group performance status 0–1, and adequate organ function who had not received chemotherapy for metastatic disease received RAM and the modified FOLFOX-6 regimen every 2 weeks. Endpoints included progression-free survival (PFS), objective response rate, overall survival, and safety. The sample size wa…

Vascular Endothelial Growth Factor ACancer ResearchPathologymedicine.medical_specialtyOrganoplatinum CompoundsAngiogenesisColorectal cancerLeucovorinAntibodies Monoclonal HumanizedDisease-Free SurvivalDrug Administration ScheduleRamucirumabchemistry.chemical_compoundAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansNeoplasm Metastasisbusiness.industryClinical Trial ResultsAntibodies MonoclonalKinase insert domain receptormedicine.diseaseVascular Endothelial Growth Factor Receptor-2Vascular endothelial growth factorVascular endothelial growth factor ATreatment OutcomeOncologychemistryFluorouracilMonoclonalCancer researchFluorouracilbusinessColorectal Neoplasmsmedicine.drugProtein Binding
researchProduct

Glycolytic phenotype and AMP kinase modify the pathologic response of tumor xenografts to VEGF neutralization.

2011

Abstract VEGF antagonists are now widely used cancer therapeutics, but predictive biomarkers of response or toxicity remain unavailable. In this study, we analyzed the effects of anti-VEGF therapy on tumor metabolism and therapeutic response by using an integrated set of imaging techniques, including bioluminescence metabolic imaging, 18-fluorodeoxyglucose positron emission tomography, and MRI imaging and spectroscopy. Our results revealed that anti-VEGF therapy caused a dramatic depletion of glucose and an exhaustion of ATP levels in tumors, although glucose uptake was maintained. These metabolic changes selectively accompanied the presence of large necrotic areas and partial tumor regress…

Vascular Endothelial Growth Factor ACancer Researchmedicine.medical_specialtyMagnetic Resonance SpectroscopyGlucose uptakeBiologyMiceFluorodeoxyglucose F18Internal medicineCell Line TumormedicineAnimalsHumansGlycolysisViability assayProtein kinase AAdenylate KinaseAMPKCancerNeoplasms Experimentalmedicine.diseaseWarburg effectMagnetic Resonance ImagingEndocrinologyPhenotypeOncologyCancer researchTumor necrosis factor alphaGlycolysisCancer research
researchProduct

Increased basic fibroblast growth factor release and proliferation in xenotransplanted squamous cell carcinoma after combined irradiation/anti-vascul…

2012

Novel strategies of cancer therapy combine irradiation and anti-angiogenic active compounds. However, little is known concerning the undesired cellular and molecular effects caused by this novel treatment concept. We used a mouse squamous cell carcinoma (SCC) xenotransplantation model to evaluate the potential undesired effects which compromise the success of this therapeutic combination. SCCs were subcutanously implanted in nude mice. Animals were treated with a fractionated irradiation scheme (5x4 Gy) alone or in combination with daily injections of anti-vascular endothelial growth factor (VEGF) antibodies. Controls remained untreated. Before and after treatment, resonance imaging (MRI), …

Vascular Endothelial Growth Factor ACancer Researchmedicine.medical_treatmentBasic fibroblast growth factorMice NudeBiologychemistry.chemical_compoundMiceCell Line TumormedicineAnimalsHumansGrowth factor receptor inhibitorOncogeneGrowth factorHemodynamicsCancerGeneral MedicineCell cyclemedicine.diseaseMolecular medicineXenograft Model Antitumor AssaysOncologychemistryCancer researchCarcinoma Squamous CellFibroblast Growth Factor 2A431 cellsOncology reports
researchProduct

Direct and long-term detection of gene doping in conventional blood samples

2010

The misuse of somatic gene therapy for the purpose of enhancing athletic performance is perceived as a coming threat to the world of sports and categorized as 'gene doping'. This article describes a direct detection approach for gene doping that gives a clear yes-or-no answer based on the presence or absence of transgenic DNA in peripheral blood samples. By exploiting a priming strategy to specifically amplify intronless DNA sequences, we developed PCR protocols allowing the detection of very small amounts of transgenic DNA in genomic DNA samples to screen for six prime candidate genes. Our detection strategy was verified in a mouse model, giving positive signals from minute amounts (20 μl)…

Vascular Endothelial Growth Factor ACandidate geneAthletic PerformanceBiologyPolymerase Chain ReactionDNA sequencinglaw.inventionMicelawGene dopingGeneticsAnimalsHumansTransgenesMolecular BiologyGenePolymerase chain reactionDoping in SportsGeneticsGenetic transferGenetic TherapyNucleic acid amplification techniqueDependovirusgenomic DNAGene ComponentsMolecular MedicineNucleic Acid Amplification TechniquesGene Therapy
researchProduct